Bettina Cockroft Buys Shares of ANNX $ANNX

Key Points

  • Bettina Cockroft bought 65,000 shares of Annexon, Inc. ($ANNX).
  • $ANNX last traded around $4.81.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Bettina Cockroft, insider at Annexon, Inc. ($ANNX), bought 65,000 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Annexon, Inc. Stock Down 3.2%

Shares of Annexon, Inc. ($ANNX) traded around $4.81 on Monday, down 3.2% for the day.

Last price$4.81
Market cap$936.52M
Forward P/E-4.55
Beta1.22
52-week low$2.03
52-week high$7.18
50-day MA$5.40
200-day MA$5.34
Current ratio5.53
Quick ratio5.44
Debt-to-equity0.13

Annexon, Inc. Earnings

EPS (ttm)-$1.13
Revenue (ttm)
Net margin0%
Return on equity-105.26%
Next earningsNov 9, 2026

Analysts Set New Price Targets

ConsensusBuy
Average target$14.71
High target$27
Low target$7
Analysts covering7

About Annexon, Inc.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

ExchangeNasdaqGS
SectorHealthcare
IndustryBiotechnology
HeadquartersBrisbane, CA
CEOMr. Douglas E. Love Esq., J.D.
Employees92

Get Annexon, Inc. alerts

New 13F filings, insider trades, and analyst moves on $ANNX, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.